Aldosterone in renal disease.
暂无分享,去创建一个
[1] R. Weiss,et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. , 2002, American journal of hypertension.
[2] K. Tsuchiya,et al. Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats , 2002, Hypertension.
[3] N. Yamamoto,et al. Aldosterone Is Produced From Ventricles in Patients With Essential Hypertension , 2002, Hypertension.
[4] V. Buckalew,et al. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction , 2002 .
[5] H. Mabuchi,et al. Calcineurin Inhibition Attenuates Mineralocorticoid-Induced Cardiac Hypertrophy , 2002, Circulation.
[6] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[7] G. Becker,et al. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. , 2001, The New England journal of medicine.
[8] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[9] C. Schmid,et al. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.
[10] N. Chaturvedi. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.
[11] F. Alla,et al. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.
[12] H. Rennke,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy* , 2022 .
[13] T. Meyer,et al. Effect of Angiotensin II Blockade on Renal Injury in Mineralocorticoid-Salt Hypertension , 2000, Hypertension.
[14] D. Vaughan,et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. , 2000, Kidney international.
[15] C. Delcayre,et al. Cardiac aldosterone production and ventricular remodeling. , 2000, Kidney international.
[16] T. Hostetter,et al. Role of dietary potassium in the hyperaldosteronism and hypertension of the remnant kidney model. , 2000, Journal of the American Society of Nephrology : JASN.
[17] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[18] Giuseppe Remuzzi,et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria , 1999, The Lancet.
[19] A. Delacourte. Biochemical and Molecular Characterization of Neurofibrillary Degeneration in Frontotemporal Dementias , 1999, Dementia and Geriatric Cognitive Disorders.
[20] F. Hutchison,et al. Resistance to remnant nephropathy in the Wistar-Furth rat. , 1999, Journal of the American Society of Nephrology : JASN.
[21] F. Luft,et al. Intracellular actions of angiotensin II in vascular smooth muscle cells. , 1999, Journal of the American Society of Nephrology : JASN.
[22] J. Cohn,et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. , 1998, European heart journal.
[23] T. Hostetter,et al. The renin-aldosterone axis in two models of reduced renal mass in the rat. , 1998, Journal of the American Society of Nephrology : JASN.
[24] C. Stier,et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. , 1998, Hypertension.
[25] T. Hostetter,et al. Role of Renin-Angiotensin-Aldosterone System in the Progression of Renal Disease: A Critical Review , 1998 .
[26] A. Struthers,et al. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.
[27] I. Miyamori,et al. Vascular aldosterone in genetically hypertensive rats. , 1997, Hypertension.
[28] D. Vaughan,et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. , 1997, Kidney international.
[29] T. Hostetter,et al. Role of aldosterone in the remnant kidney model in the rat. , 1996, The Journal of clinical investigation.
[30] F. Locatelli,et al. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .
[31] A. Struthers. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. , 1996, Journal of cardiac failure.
[32] J. Egido. Vasoactive hormones and renal sclerosis. , 1996, Kidney international.
[33] U. Ikeda,et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. , 1995, European journal of pharmacology.
[34] I. Miyamori,et al. Production of aldosterone in isolated rat blood vessels. , 1995, Hypertension.
[35] I. Miyamori,et al. 3. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells , 1994, The Journal of biological chemistry.
[36] M. Picken,et al. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. , 1994, Journal of the American Society of Nephrology : JASN.
[37] R. Dilley,et al. Mineralocorticoids, hypertension, and cardiac fibrosis. , 1994, The Journal of clinical investigation.
[38] R. Spiro,et al. Synthesis of Type VI Collagen by Cultured Glomerular Cells and Comparison of Its Regulation by Glucose and Other Factors With That of Type IV Collagen , 1994, Diabetes.
[39] L. Kornel. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells , 1994 .
[40] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[41] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[42] W. G. Walker. Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] K. Weber,et al. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. , 1992, The Journal of laboratory and clinical medicine.
[44] T. Hostetter,et al. Renin expression in renal ablation. , 1992, Hypertension.
[45] T. Meyer,et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. , 1992, The Journal of clinical investigation.
[46] L. Dworkin,et al. Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. , 1992, Kidney international.
[47] C. Alpers,et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. , 1992, Kidney international.
[48] G. Hill,et al. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. , 1992, Kidney international.
[49] A. Cowley,et al. Long-term control of arterial blood pressure. , 1992, Physiological reviews.
[50] T. Hostetter,et al. Glomerular renin synthesis and storage in the remnant kidney in the rat. , 1991, Kidney international.
[51] B. Delman,et al. Adriamycin-induced increase in serum aldosterone levels: effects in riboflavin-sufficient and riboflavin-deficient rats. , 1990, Endocrinology.
[52] J. Dominguez,et al. Evidence that angiotensin-II and potassium collaborate to increase cytosolic calcium and stimulate the secretion of aldosterone. , 1989, Endocrinology.
[53] L. Ruilope,et al. Converting enzyme inhibition in chronic renal failure. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[54] J. Miralles,et al. Hyporeninemic hypoaldosteronism in diabetic patients with chronic renal failure. , 1988, American journal of nephrology.
[55] D. Schlondorff. The glomerular mesangial cell: an expanding role for a specialized pericyte , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[56] J. Bauer,et al. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. , 1986, Archives of internal medicine.
[57] B. Brenner,et al. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. , 1986, The Journal of clinical investigation.
[58] S. Linas,et al. Effect of potassium depletion on two-kidney, one-clip renovascular hypertension in the rat. , 1985, Kidney international.
[59] B. Brenner,et al. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. , 1984, The Journal of clinical investigation.
[60] D. Young,et al. Experimental Aldosterone Hypertension in the Dog , 1982, Hypertension.
[61] R. Hené,et al. Plasma aldosterone concentrations in chronic renal disease. , 1982, Kidney international.
[62] J. Staessen,et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.
[63] R. Tarazi,et al. Sodium, Extracellular Fluid Volume, and Cardiac Output Changes in the Genesis of Mineralocorticoid Hypertension in the Intact Dog , 1979, Hypertension.
[64] T. Berl,et al. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. , 1978, Kidney international.
[65] P. Weidmann,et al. Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. , 1977, Kidney international.
[66] S. Klahr,et al. Pathogenesis of the glomerulopathy associated with renal infarction in rats. , 1976, Kidney international.
[67] B. J. Tucker,et al. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. , 1976, The Journal of clinical investigation.
[68] J. Baum,et al. NATIONAL DRIED MILK , 1975, The Lancet.
[69] T. Ferris,et al. Renin secretion in renal hypertension. , 1970, Lancet.
[70] Morrison Ab. Experimentally induced chronic renal insufficiency in the rat. , 1962 .